Home > Haematology > EHA 2021 > Lymphoma > Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By
Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA
Conference
EHA 2021
Treatment with naratuximab emtansine + rituximab for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin’s lymphomas (B-NHL) demonstrated high efficacy and a tolerable and manageable safety profile in a phase 2 study. This treatment regimen could offer a new treatment option for these patients, including heavily pre-treated patients. Patients with r/r B-NHL and particularly r/r DLBCL who are not candidates for stem cell transplantation or CAR T-cell therapy have a poor prognosis. A surface antigen of B lymphocytes, CD37, is highly expressed in NHL and thus a potential target for therapies. Naratuximab emtansine is an antibody-drug conjugate consisting of the humanised anti-CD37 antibody K7153A that targets CD37. A phase 1 monotherapy study demonstrated a good safety profile with a 22% objective response rate (ORR) in patients with DLBCL (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on